Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group studyAlan F. List, Frederick R. Appelbaum, Diane L. Persons et al.|Blood|2001Cited by 419
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphomaPaul M. Barr, Margaret M. Briehl, Thomas P. Miller et al.|Blood|2014Cited by 37